Recent studies have converged on the convergence of GLP-1|GIP|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GLP agonists are widely employed for managing type 2 diabetes, their potential effects on reinforcement circuits, specifically influenced by DA pathways, are gaining substantial attention. This article provid